Cargando…

Personalized treatment for advanced colorectal cancer: KRAS and beyond

Targeted therapies have improved the survival of patients with advanced colorectal cancer (CRC). However, further improvements in patient outcomes may be gained by the development of predictive biomarkers in order to select individuals who are most likely to benefit from treatment, thus personalizin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Gargi Surendra, Karapetis, Christos S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839845/ https://www.ncbi.nlm.nih.gov/pubmed/24294007 http://dx.doi.org/10.2147/CMAR.S35025

Ejemplares similares

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Zhu, Gongmin, et al.
Publicado: (2021)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

KRAS-associated microRNAs in colorectal cancer
por: Ibrahim, Hamizah, et al.
Publicado: (2020)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

Targeting KRAS(G12C)-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
por: Ji, Jingran, et al.
Publicado: (2022)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
por: László, Loretta, et al.
Publicado: (2021)

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
por: Bteich, Fernand, et al.
Publicado: (2023)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry
por: Tapia Rico, Gonzalo, et al.
Publicado: (2017)

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
por: Reece, Mifanwy, et al.
Publicado: (2019)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
por: Ternet, Camille, et al.
Publicado: (2021)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
por: Pal, Rekha, et al.
Publicado: (2018)

Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
por: Hasbullah, Hidayati Husainy, et al.
Publicado: (2021)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer
por: Sharma, Abha, et al.
Publicado: (2016)

Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
por: Kim, Seung Tae, et al.
Publicado: (2015)

KRAS mutations in patients with colorectal cancer in Libya
por: Abudabous, Asma, et al.
Publicado: (2021)

Targeted therapy for esophagogastric cancers: a review
por: Khattak, Muhammad A, et al.
Publicado: (2012)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives
por: Motta, Rodrigo, et al.
Publicado: (2021)

The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
por: Segelov, E, et al.
Publicado: (2014)

Colorectal Cancer Biomarkers in the Era of Personalized Medicine
por: Patel, Jai N., et al.
Publicado: (2019)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
por: Shu, Chun-Lu, et al.
Publicado: (2022)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
por: Chang, David Z, et al.
Publicado: (2009)

Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review
por: El Asri, Achraf, et al.
Publicado: (2020)

Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era
por: Ciardiello, D., et al.
Publicado: (2022)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_450shv9e50v8vvgc3dt82ph7of